A Phase 2/3 interventional study of Rogaratinib (BAY1163877) and Chemotherapy in Carcinoma, Transitional Cell, sponsored by Bayer. Completed at 161 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Bayer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Carcinoma, Transitional Cell with a site in Japan — 12 open to participants now, 15 under way, 5 of them phase 3. Carcinoma, Transitional Cell · Japan.
Among the 38 studies in Carcinoma, Transitional Cell with a site in Japan, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2/3, and was the 12th registered.
632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →12 of the 38 studies in Carcinoma, Transitional Cell with a site in Japan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Japan, United States, Australia and 13 more countries
Ages 18+
Genmab · Sites in Japan, United States, Spain
Ages 18+
Pfizer · Sites in Japan, United States, Australia and 3 more countries
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in Japan, United States
Ages 18+
Eli Lilly and Company · Sites in Japan, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 14 · Phase 3 12
First in 2004; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 175 across the 35 interventional studies, 360 across the 3 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 38 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 3 studies filed under Carcinoma, Transitional Cell — fewer than ten, so there is no comparison to draw.
6 of the studies in Carcinoma, Transitional Cell with a site in Japan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT04879329Seagen, a wholly owned subsidiary of PfizerA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | 2026-12-11 |
| NCT06310759Tampere University HospitalProspective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer | 2026-12-31 |
| NCT06632951AbbVieStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 38 studies in Carcinoma, Transitional Cell with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.
The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in terms of objective response rate (before: overall survivial) of urothelial carcinoma patients with FGFR positive tumors.
At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented urothelial carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis, ureters, urethra meeting all of the following criteria
Exclusion Criteria:
Previous or concurrent cancer except
History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rogaratinib treatment study arm, comprising 1. Pre-treatment period, including FGFR testing and screening, 2. Treatment period, and 3. Follow-up period, including active follow-up and long-term follow-up. Patients will be considered "on study" during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered "off study".
Drug: Rogaratinib (BAY1163877)
Chemotherapy treatment study arm, comprising 1. Pre-treatment period, including FGFR testing and screening, 2. Treatment period, and 3. Follow-up period, including active follow-up and long-term follow-up. Patients will be considered "on study" during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered "off study".
Drug: Chemotherapy
Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
Objective Response Rate (ORR) - Central Assessment
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR). participants for whom overall best response is not CR or PR, as well as participants without any post-baseline tumor assessment will be considered non-responders.
Time frame: From start of treatment up to end of active follow-up, approximately 29 months
Disease-control Rate (DCR) - Central Assessment
DCR was defined as the percentage of participants whose overall best response was not a progressive disease (i.e., CR, PR, stable disease \[SD\] or Non CR/Non PD).
Time frame: From start of treatment till end of active follow-up, approximately 29 months
Progression-free Survival (PFS) - Central Assessment
Progression free survival (PFS) was defined as the time (days) from randomization to date of first observed disease progression (radiological or clinical assessment or both) or death due to any cause (if death occurred before progression was documented).
Time frame: From start of treatment till end of active follow-up, approximately 29 months
Duration of Response (DOR) - Central Assessment
DOR (for patients with PR and CR only) was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression (including symptomatic deterioration) or death, whichever was earlier
Time frame: From start of treatment till end of active follow-up, approximately 29 months
Number of Participants With Treatment Emergent Adverse Events
A treatment-emergent event was defined as any event arising or worsening after the start of study drug administration until 30 days after the last administration of study treatment
Time frame: From start of treatment up to 30 days after the last administration of study treatment, approximately 29 months
This study enrolled participants at 111centers in 28 countries from 31 MAY 2018 (first participant first visit) to 27 OCT 2020 (last participant last visit).
| Milestone | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population |
|---|---|---|
| Started | 87 | 88 |
| Started treatment | 86 | 82 |
| Active follow-up performed | 61 | 56 |
| Entered long term follow-up | 56 | 69 |
| Completed | 0 | 0 |
| Not completed | 87 | 88 |
| Withdrew: Disc trt: withdrawal by participant | 6 | 4 |
| Withdrew: Disc trt: lost to follow up | 0 | 1 |
| Withdrew: Disc trt: radiological progression | 58 | 50 |
| Withdrew: Disc trt: other | 1 | 0 |
| Withdrew: Study drug never administered | 1 | 6 |
| Withdrew: Discontinued (disc) treatment (trt): death | 6 | 4 |
| Withdrew: Disc trt: adverse event (ae) | 13 | 9 |
| Withdrew: Disc trt: physician decision | 0 | 5 |
| Withdrew: Disc trt: clinical progression | 1 | 5 |
| Withdrew: Disc trt:ae not asso. w/ clinical disease progress | 1 | 4 |
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR). participants for whom overall best response is not CR or PR, as well as participants without any post-baseline tumor assessment will be considered non-responders.
| percentage of participants | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Rogaratinib_WT Population | Chemotherapy_WT Population |
|---|---|---|---|---|
| Objective Response Rate (ORR) - Central Assessment | 19.5 (11.8 to 29.4) | 21.6 (13.5 to 31.6) | 19.4 (10.4 to 31.4) | 23.8 (14.0 to 36.2) |
DCR was defined as the percentage of participants whose overall best response was not a progressive disease (i.e., CR, PR, stable disease \[SD\] or Non CR/Non PD).
| percentage of participants | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Rogaratinib_WT Population | Chemotherapy_WT Population |
|---|---|---|---|---|
| Disease-control Rate (DCR) - Central Assessment | 50.6 (39.6 to 61.5) | 55.7 (44.7 to 66.3) | 53.2 (40.1 to 66.0) | 63.5 (50.4 to 75.3) |
Progression free survival (PFS) was defined as the time (days) from randomization to date of first observed disease progression (radiological or clinical assessment or both) or death due to any cause (if death occurred before progression was documented).
| months | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Rogaratinib_WT Population | Chemotherapy_WT Population |
|---|---|---|---|---|
| Progression-free Survival (PFS) - Central Assessment | 2.7 (1.6 to 4.6) | 3.2 (2.7 to 4.4) | 2.8 (2.6 to 5.1) | 4.0 (2.8 to 6.1) |
DOR (for patients with PR and CR only) was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression (including symptomatic deterioration) or death, whichever was earlier
| months | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Rogaratinib_WT Population | Chemotherapy_WT Population |
|---|---|---|---|---|
| Duration of Response (DOR) - Central Assessment | 4.9 (2.2 to 7.0) | 5.8 (3.5 to 7.7) | 5.1 (1.5 to 9.2) | 7.0 (2.7 to 8.4) |
A treatment-emergent event was defined as any event arising or worsening after the start of study drug administration until 30 days after the last administration of study treatment
| Participants | Rogaratinib (BAY1163877) | Chemotherapy |
|---|---|---|
| Any TEAE | 86 | 82 |
| Any drug related TEAE | 81 | 76 |
Collected over Approximately 29 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rogaratinib (BAY1163877) | 47/86 (54.7%) | 39/86 (45.3%) | 85/86 (98.8%) |
| Chemotherapy | 45/82 (54.9%) | 33/82 (40.2%) | 77/82 (93.9%) |
| Event | Rogaratinib (BAY1163877) | Chemotherapy |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/86 | 4/82 |
| NeutropeniaBlood and lymphatic system disorders | 0/86 | 4/82 |
| Urinary tract infectionInfections and infestations | 1/86 | 4/82 |
| DeathGeneral disorders | 4/86 | 2/82 |
| General physical health deteriorationGeneral disorders | 4/86 | 1/82 |
| SepsisInfections and infestations | 0/86 | 3/82 |
| HaematuriaRenal and urinary disorders | 1/86 | 3/82 |
| Abdominal painGastrointestinal disorders | 3/86 | 0/82 |
| Acute kidney injuryRenal and urinary disorders | 3/86 | 2/82 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/86 | 0/82 |
| Event | Rogaratinib (BAY1163877) | Chemotherapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 48/86 | 18/82 |
| HyperphosphataemiaMetabolism and nutrition disorders | 39/86 | 0/82 |
| Decreased appetiteMetabolism and nutrition disorders | 36/86 | 21/82 |
| ConstipationGastrointestinal disorders | 25/86 | 29/82 |
| AnaemiaBlood and lymphatic system disorders | 11/86 | 28/82 |
| FatigueGeneral disorders | 21/86 | 28/82 |
| NauseaGastrointestinal disorders | 27/86 | 20/82 |
| AlopeciaSkin and subcutaneous tissue disorders | 20/86 | 24/82 |
| AstheniaGeneral disorders | 25/86 | 19/82 |
| NeutropeniaBlood and lymphatic system disorders | 3/86 | 19/82 |
| Age, Continuous(years) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Mean | 67.7 ± 8.3 | 66.4 ± 10.3 | 67.0 ± 9.3 |
| Sex: Female, Male(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Female | 75 | 70 | 145 |
| Male | 12 | 18 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 76 | 78 | 154 |
| Unknown or Not Reported | 10 | 10 | 20 |
| Race (NIH/OMB)(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 23 | 25 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 55 | 55 | 110 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 8 | 16 |
| Cancer Category(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Location of primary cancer: bladder | 56 | 45 | 101 |
| Location of primary cancer: Ureter | 17 | 14 | 31 |
| Location of primary cancer: Renal pelvis | 12 | 28 | 40 |
| Location of primary cancer: Proximal urethra | 2 | 1 | 3 |
| Cancer stage at study entry(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Stage III B | 1 | 3 | 4 |
| Stage IV | 5 | 12 | 17 |
| Stage IV A | 13 | 24 | 37 |
| Stage IV B | 67 | 48 | 115 |
| Unknown | 1 | 1 | 2 |
| PIK3CA and/or RAS activating mutations(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Absent | 65 | 69 | 134 |
| Present | 10 | 10 | 20 |
| Unknown | 12 | 9 | 21 |
| FGFR expression from Targos(Participants) | Rogaratinib (BAY1163877)_Overall Population | Chemotherapy_Overall Population | Total |
|---|---|---|---|
| Negative | 13 | 14 | 27 |
| Positive | 69 | 69 | 138 |
| Not assessed | 5 | 5 | 10 |
Showing the first 100 of 161 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Oct 2020, 28 months.
Results were first posted in Dec 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rogaratinib
Carcinoma, Transitional Cell →